Autres langues Transgene

Actions

TNG

FR0005175080

Marché Fermé - Euronext Paris Autres places de cotation 14:56:19 24/04/2024			Varia. 5j.	Varia. 1 janv.
1,346 ^EUR	+1,82 %		-7,17 %	-1,75 %

15/04	Transgene : plus forte hausse du marché SRD à la mi-séance du lundi 15 avril 2024	AO
11/04	Transgene : plus forte hausse du marché SRD à la clôture du jeudi 11 avril 2024 -	AO

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024	24/04
Availability of Transgene's 2023 Universal Registration Document	11/04
Actualización de las fuertes variaciones del día: HSBC, Barry Callebaut y WPP en verde	10/04
Transgene : présente les résultats d'un vaccin à l'AACR	10/04
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024	09/04
Transgene CFO Steps Down; Successor Assumes Office	28/03
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025	27/03
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer	27/03
Transgene SA Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Transgene SA Announces Chief Financial Officer Changes	27/03
Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee	27/03
Transgene Announces Upcoming Investor Meetings	18/03
Transgene Announces Upcoming Investor Meetings	18/03
Fractyl Health Reports 'Promising' Preclinical Findings From Rejuva Platform; Shares Fall	12/03
EN DIRECTO DESDE LOS MERCADOS: Indra, Acciona, Sabadell, Unicaja, Bankinter, BBVA, Cellnex , DHL, Temenos ...	06/03
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024	06/03
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024	06/03
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	05/03
Transgene, NEC Corporation and BostonGene Corporation Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	05/03
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050	05/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Transgene

Actions

TNG

FR0005175080

Autres langues

Filtres